Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum
June 21 2021 - 7:35AM
Diffusion Pharmaceuticals Inc. (NASDAQ:
DFFN) (“Diffusion” or the “Company”), an innovative
biopharmaceutical company developing novel therapies that enhance
the body’s ability to deliver oxygen to areas where it is needed
most, today announced that CEO Robert Cobuzzi, Jr., Ph.D., will
present via webcast at the Life Sciences Investor Forum being held
on June 24, 2021.
Details of Diffusion's presentation are as
follows:
Event: |
|
Life Sciences Investor Forum |
Date: |
|
Thursday, June 24, 2021 |
Time: |
|
11:30 a.m., EDT |
Link: |
|
https://www.lifesciencesinvestorforum.com/events/event-details/agenda |
During the presentation, Dr. Cobuzzi will
discuss Diffusion Pharmaceuticals’ business strategy, which focuses
on developing Trans Sodium Crocetinate to treat a variety of
diseases driven by hypoxemia.
Company Highlights:
- Completed
enrollment and dosing in the TCOM 200-301 study in March 2021
- Announced data
from the COVID-19 100-303 study in February 2021
- Raised $34.5
million in financing in February 2021.
This will be a live presentation. If attendees
are not able to join the event live on the day of the conference,
an archived webcast will also be made available after the
event.
About Life Sciences Investor
Forum:
Life Sciences Investor Forum is the leading
proprietary investor conference series that provides an interactive
forum for Life Sciences companies to meet with and present directly
to investors.
A real-time solution for investor engagement,
Life Sciences Investor Forum is powered by Intrado Digital Media
and specifically designed for more efficient investor access.
Replicating the look and feel of on-site investor conferences, Life
Sciences Investor Forum combines leading-edge conferencing and
investor communications capabilities with a comprehensive global
investor audience network.
About Diffusion Pharmaceuticals
Inc.
Diffusion Pharmaceuticals Inc. is an innovative
biopharmaceutical company developing novel therapies that enhance
the body’s ability to deliver oxygen to areas where it is needed
most. Diffusion’s lead product candidate, TSC, is being developed
to enhance the diffusion of oxygen to tissues with low oxygen
levels, also known as hypoxia, a serious complication of many of
medicine’s most intractable and difficult-to-treat conditions. In
addition to TSC, Diffusion’s product candidate DFN-529, a novel,
allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage
development. For more information, please visit us at
www.diffusionpharma.com.
Forward-Looking Statements
This press release includes express and implied
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended, including
regarding the Company’s planned presentation at the Life Sciences
Investor Forum and the contents thereof. The Company may, in some
cases, use terms such as “believes,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” “approximately,” or other words that convey uncertainty
of future events or outcomes to identify these forward-looking
statements. Although the Company believes that it has a reasonable
basis for each forward-looking statement contained herein,
forward-looking statements by their nature involve risks and
uncertainties, known and unknown, many of which are beyond the
Company’s control, and as a result the Company’s actual results
could differ materially from those expressed or implied in any
forward-looking statement. Particular risk and uncertainties
include, among other things, those related to: the Company’s
ability to design, initiate, enroll, execute, and complete its
ongoing and planned studies evaluating TSC; general economic,
political, business, industry, and market conditions, including the
ongoing COVID-19 pandemic; and the other factors discussed under
the heading “Risk Factors” in the Company’s filings most recent
Annual Report on Form 10-K and other filings with the U.S.
Securities and Exchange Commission. Any forward-looking statements
in this press release speak only as of the date hereof (or such
earlier date as may be identified) and, except as required by
applicable law, rule, or regulation, the Company undertakes no
obligation to update any such statements after the date hereof.
ContactsInvestors:Tiberend
Strategic Advisors, Inc.Maureen McEnroe, CFA/Lisa
Shermmcenroe@tiberend.com / lsher@tiberend.com
Media:Kate BarretteRooneyPartners(212)
223-0561Kbarrette@rooneyco.com
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Apr 2023 to Apr 2024